Business Wire

Kinaset Therapeutics Launches with a $40M Series A Financing to Develop Novel Therapeutics for Respiratory Diseases and an Exclusive Global License Agreement with Vectura Group for KN-002 (VR588), a Novel Anti-Inflammatory

Share

Kinaset Therapeutics, Inc. (“Kinaset” or the “Company”), a newly-founded biopharmaceutical company, today announced a $40 million Series A financing with a blue-chip investor syndicate of 5AM Ventures, Atlas Venture, and Gimv. The Company also announced an exclusive global in-license and services agreement with Vectura Group plc (LSE: VEC) (“Vectura”) to develop and commercialize KN-002 (formerly known as VR588), a novel, inhaled small-molecule pan-JAK inhibitor, for the treatment of eosinophilic and non-eosinophilic severe asthma. A Phase 1/1b clinical trial in healthy volunteers and patients is poised to begin in the first half of 2021.

Kinaset is led by an experienced management team and Board of Directors with strong backgrounds in the development of respiratory therapeutics. The company is led by Chief Executive Officer Robert Clarke (formerly Pulmatrix, AIR/Alkermes), Chief Business Officer Roger Heerman (GlaxoSmithKline, Vectura), and Chief Development Officer Frazer Morgan (Vectura, 3M), each of whom has over 20 years of experience in the industry. Thomas B. King (Alexza, Vivus), Chairman of the Board, is joined on the Kinaset Board of Directors by founding investors Jamil Beg (5AM), Kevin Bitterman (Atlas), and Bram Vanparys (Gimv).

Kinaset is responsible for the overall development and commercialization of KN-002, with Vectura providing formulation development expertise and manufacturing of clinical trial supplies. The Company will pay Vectura fees for development services, certain regulatory and commercial milestones, and future royalties on global net sales in return for the license.

“I am excited to be part of Kinaset Therapeutics and their plans to deliver a next-generation therapeutic for the severe asthma population. The highly experienced management team and board coupled with the exclusive global license from Vectura provide a great springboard for the launch of Kinaset,” said Thomas B. King. He added “Vectura’s profile as a world-class CDMO with multiple approved inhaled therapeutics make them a trusted partner as we move KN-002 to our upcoming clinical trial.”

Robert Clarke, Ph.D., Chief Executive Officer, and a co-founder of Kinaset Therapeutics, commented on the company and the KN-002 program, “Our goal is to build Kinaset into a leading respiratory therapeutics company focused on patients starting with KN-002. Severe asthmatics continue to suffer from the limited availability of safe and effective treatment options. We believe that our inhaled pan-JAK inhibitor, KN-002, has the potential to be a best-in-class therapeutic for this population. In addition, KN-002 could be a less-invasive and more cost-effective alternative to currently approved parenteral biologicals used in the treatment of severe asthma.”

Jamil M. Beg, Partner at 5AM Ventures and Director at Kinaset, commented, “The field of respiratory drug development has made incredible strides over recent years. Biologics have validated immunomodulatory approaches and advanced the standard of care for patients. However, there remains a significant need and burden on patients, especially in the severe asthma population. We see KN-002 as having transformational potential for patients and are excited to support a dedicated team at Kinaset that is building the next leading respiratory disease company.”

Unmet Clinical Needs

Asthma is a complex and heterogeneous disease affecting over 300 million people worldwide, with approximately 10% of patients having severe asthma1,2. Subjects with severe uncontrolled asthma suffer from frequent exacerbations, compromised lung function, and a reduced quality of life1-3. This group is associated with a disproportionate number of asthma-related hospitalizations and accounts for approximately 50% of asthma-related costs.4,5

Multiple inflammatory pathways are implicated in the pathogenesis of asthma6-8. Eosinophilic asthma, characterized by elevated levels of blood eosinophils and fractional exhaled nitric oxide8, accounts for about two-thirds of patients with severe asthma8. Conversely, a large proportion of subjects do not exhibit an eosinophilic profile and suffer from an inadequate response to parenteral biologicals and oral corticosteroids resulting in a loss of asthma control1-3. Therefore, additional therapeutics to support these non-eosinophilic patients represent a significant need in asthma control.

About Kinaset Therapeutics, Inc.

At Kinaset Therapeutics, we intend to develop novel therapeutics that can positively impact people affected by intractable diseases, including severe asthma. Our novel lead asset and experienced team combine a potentially best in class approach to treating severe asthma with a group of dedicated drug development experts working to bring the therapy forward. More information can be found at www.kinasettherapeutics.com.

About Vectura

Vectura is a provider of innovative inhaled drug delivery services that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation, and development capabilities to deliver a broad range of complex inhaled therapeutics.

For further information, please visit Vectura's website at www.vectura.com.

References:
1 Kupczyk M, Wenzel S. J Intern Med 2012;272:121–32.
2 Wenzel S. Am J Respir Crit Care Med. 2005; 172; 149–60.
3 Chung KF, Wenzel SE, Brozek JL, et al. Eur Respir J 2014; 43: 343–73.
4 Price D, Fletcher M, van der Molen T. NPJ Prim Care Respir Med 2014; 12; 24: 14009.
5 World Allergy Organization (WAO). (https://www.worldallergy.org/educational_programs/world_allergy_forum/anaheim2005/blaiss.php [Last accessed: September 2020])
6 Godar M, Blanchetot C, de Haard H, et al. MAbs. 2018; 10 (1): 34–45.
7 Peters MC, Mekonnen ZK, Yuan S, et al. J Allergy Clin Immunol. 2014; 133: 388–94.
8 Fahy JV. Nat Rev Immunol. 2015; 15: 57-65.

Contact information

Roger Heerman – Chief Business Officer
info@kinasettx.com
+1 508-858-5810

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Verimatrix Releases Advanced Code Protection Service for Android Application Bundles20.1.2021 19:45:00 EETPress release

Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced general availability of version 2.2 of the Verimatrix Application Protection service for Android. The company’s latest Code Protection service for Android applications now supports the forthcoming Android ecosystem change that will mandate the use of Android Application Bundles (AABs) in the second half of 2021. A significant shift for developers, the upcoming AAB mandate creates a need for simple, reliable software security that prevents app attacks. In addition to traditional APKs, the Verimatrix Application Protection service now also supports AABs defined by Google Play’s publishing guidelines. Other new features and in enhancements in Verimatrix Application Protection service for Android include: AAB support through the Verimatrix App Shield service or on-premise tool Upgraded whole app integrity verification based on certificate binding for pu

LG CHEM TO SEEK INNOVATIVE IDEAS FOR SUSTAINABLE TECHNOLOGIES WORLDWIDE THROUGH 3rd GLOBAL INNOVATION CONTEST20.1.2021 17:00:00 EETPress release

LG Chem (KRX: 051910) announced on 20th January that it will host the 3rd Global Innovation Contest (GIC) for leading universities and research institutions worldwide. Being the first of its kind in the Korean chemical industry, Global Innovation Contest invites organizations around the world to discover innovative ideas for sustainable technologies. The contest is open for entry from 25th January to 31st March in 4 categories: Energy, Sustainability, Advanced Materials, and Digital Transformation (DX). Under the new vision of the company “We connect science to life for a better future,” Sustainability and DX are 2 categories newly added this year. All scholars and researchers interested in developing the next generation’s innovative technology and industry-academia collaboration research are welcome to participate and submit their research proposals through the official GIC website. (www.rnd.lgchem.com/global/gic) LG Chem will form a judging panel of internal experts to evaluate the r

H.I.G. Capital Sells RGIB's Bathroom Furniture Division to Roca20.1.2021 16:20:00 EETPress release

H.I.G. Capital, ("H.I.G."), a leading global private equity investment firm with over €35 billion of equity capital under management, and the Royo family have entered into an agreement to sell the bathroom furniture division of RG International Bathroom (“RGIB or the “Company”) to Roca Sanitario, S.A. The Royo family will retain a minority stake in the division. Both H.I.G. and the Royo family will continue as shareholders of the shower tray business of RGIB, operating under the Fiora brand. H.I.G. partnered with the Royo family in December 2016 and has achieved a number of important milestones, including: Developing a new factory and brand in Poland (Maximus) that contributed to strengthening the leading position that RGIB already had in the Polish market under the Elita brand Entering new segments, channels and countries; one of the most relevant achievements was the entry into the DIY channel in Germany where RGIB is now a leading player Consolidating RGIB’s leading position in Spai

Thales NS50 Radar to Equip the Belgium Navy and the Royal Netherlands Navy Next Generation Mine Counter Measures Vessels (MCMV)20.1.2021 12:00:00 EETPress release

The navies of Belgium and the Netherlands rely on Thales, Naval Group and KERSHIP shipyard to equip the 12 next generation Mine Counter Measures Vessels with NS50 radars for Air & Surface Surveillance with Fire Control capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210120005024/en/ NS50 radar © Thales The NS50 provides for the first time a complete and superior level of self-protection capability against air and surface threats for this category of high value MCM vessels. A strategic choice for small to medium vessels, the NS50 offers dual functions between air and surface surveillance and fire control. The nature of threats faced by Navies has never been more varied nor more challenging, ranging from next generation anti-ship missiles, robotic warfare and swarm attacks, to electronic warfare (jamming) as well as, overall, having to operate in a simultaneously conventional, asymmetric and hybrid threat environm

SmartStream Reveal Their Latest API Suite With a Complete Range of Reference Data Services20.1.2021 12:00:00 EETPress release

SmartStream Technologies, the financial Reference Data Utility (RDU) solutions provider, today announces the launch of its Application Programming Interface (API) suite – for quicker access to services providing accurate data, with improved customer service, operational efficiency, greater agility and competitiveness. The new fully comprehensive API service will benefit financial institutions by saving huge amounts on infrastructure costs, as well as an affordable service which is straightforward to deploy. Financial institutions are now realising the need for change, with many currently engaging in digital transformation projects including the implementation of APIs. RDU services currently fall into two categories: security reference data and regulatory reference data. Security reference data solutions available on an API basis will include a listed derivatives service, with data sourced from over 100 exchanges and comprehensive coverage for options, futures, options on futures and ca

ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer20.1.2021 10:00:00 EETPress release

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca’s ENHERTU® (trastuzumab deruxtecan) has been granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens. In Europe, approximately 531,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive.1,2,3 The impact of the disease is significant, with breast cancer responsible for more than 141,000 deaths per year in Europe.1 “One in five women with breast cancer have HER2 positive disease and those with previously-treated metastatic disease often progress quickly,” said Professor Fabrice André, Head of Research, Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France. “One of the biggest challenges in this setting has been identifying treatment strategies that produce

Bureau Veritas Further Expands Cybersecurity Offer by Joining Forces With Secura20.1.2021 10:00:00 EETPress release

Bureau Veritas , a world leader in testing, inspection and certification, announced today that it has completed the acquisition of Secura B.V. (starting with a majority stake), an independent service company specializing in cybersecurity services. Secura will be a cornerstone in the cybersecurity strategy of Bureau Veritas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119006117/en/ Rising demand in digital security and new regulations drive a growing need for conformity assessments. As a result, Testing, Inspection and Certification (TIC) services for cybersecurity are an emerging market with substantial expected growth and significant momentum. In this promising new conformity market, Secura is a recognized cybersecurity player with a strong orientation toward TIC activities. Established in 2000 in the Netherlands, Secura has 100 employees located in two technological centers in Eindhoven and Amsterdam. The company pos

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom